Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.35 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | STAT6 | P42226 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.35 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.35 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1697515 | 0.97 | SMN1; SMN2 (0.38) | TP53SMN1; SMN2MAPK1HSD17B10LMNA | |
| SCHEMBL15922897 | 0.88 | TP53 (0.41) | TP53SMN1; SMN2MAPK1HSD17B10LMNA | |
| SCHEMBL20032903 | 0.84 | HTT (0.40) | TP53TSHRATMEPHX2POLB | |
| SCHEMBL16307931 | 0.84 | HTT (0.40) | TP53TSHRATMEPHX2POLB | |
| SCHEMBL1143530 | 0.81 | TP53 (0.41) | TP53SMN1; SMN2MAPK1HSD17B10LMNA | |
| SCHEMBL15922741 | 0.78 | TP53 (0.39) | TP53SMN1; SMN2MAPK1HSD17B10LMNA | |
| SCHEMBL11355878 | 0.78 | HSD11B1 (0.41) | TP53SMN1; SMN2MAPK1HSD17B10LMNA | |
| SCHEMBL19073248 | 0.77 | TP53 (0.36) | TP53SMN1; SMN2MAPK1HSD17B10LMNA | |
| SCHEMBL18177915 | 0.77 | HTT (0.47) | TP53SMN1; SMN2MAPK1SIGMAR1TSHR | |
| SCHEMBL15922928 | 0.76 | HSD11B1 (0.43) | TP53SMN1; SMN2TSHRGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160331727-A9 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-11-17 | — | — | US | claimed |
| US-20160000757-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-01-07 | — | — | US | claimed |
| US-9072729-B2 | Method for treating fibrosis and cancer with imidazolium and imidazolinium compounds | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-07-07 | — | — | US | claimed |
| EP-2803356-A1 | Method for treating neurological disorders with imidazolium and imidazolinium compounds | Agency for Science, Technology and Research (SG) | 2014-11-19 | — | — | EP | claimed |
| US-20110178040-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-07-21 | — | — | US | claimed |
| US-20110028513-A1 | METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-02-03 | — | — | US | claimed |
| EP-2271338-A1 | METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | Agency for Science, Technology And Research (SG) | 2011-01-12 | — | — | EP | claimed |
| EP-2249832-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | Agency for Science, Technology And Research (SG) | 2010-11-17 | — | — | EP | claimed |
| WO-2009123569-A1 | METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-10-08 | — | — | WO | claimed |
| WO-2009096905-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-08-06 | — | — | WO | claimed |
| US-20060128935-A1 | Manufacture of macrocyclic polyester oligomers | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-06-15 | — | — | US | claimed |
| CN-122036785-A | IVB metal complex containing imidazoline (alkyl) -2-imino, catalyst system and method for preparing polymer by using IVB metal complex | 东华大学 | 2026-05-15 | — | — | CN | disclosed |
| WO-2024085044-A1 | POLYMERIZABLE COMPOSITION AND NORBORNENE RESIN | RIMTEC株式会社 | 2024-04-25 | — | — | WO | disclosed |
| WO-2024085043-A1 | CATALYST LIQUID AND POLYMERIZABLE COMPOSITION | RIMTEC株式会社 | 2024-04-25 | — | — | WO | disclosed |
| EP-2444438-B1 | POLYMERIZABLE COMPOSITION, RESIN MOLDED BODY, AND LAMINATE | ZEON CORP (JP) | 2020-03-18 | — | — | EP | disclosed |
| US-20030050406-A1 | Process for producing hydrogenated product of cyclic olefin polymer prepared through ring-opening polymerization | ZEON CORPORATION | 2003-03-13 | — | — | US | disclosed |
| US-20030018138-A1 | Copolymer formed by ring -opening polymerization, product of hydrogenation of copolymer formed by ring-opening polymerization, and process for producing these | ZEON CORPORATION (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1275675-A1 | COPOLYMER FORMED BY RING-OPENING POLYMERIZATION, PRODUCT OF HYDROGENATION OF COPOLYMER FORMED BY RING-OPENING POLYMERIZATION, AND PROCESSES FOR PRODUCING THESE | Zeon Corporation (JP) | 2003-01-15 | — | — | EP | disclosed |
| US-6486264-B1 | Process for producing hydrogenated ring-opening polymerization polymer of cycloolefin | ZEON CORPORATION (JP) | 2002-11-26 | — | — | US | disclosed |
| EP-1197509-A1 | PROCESS FOR PRODUCING HYDROGENATED RING-OPENING POLYMERIZATION POLYMER OF CYCLOOLEFIN | Nippon Zeon Co., Ltd. (JP) | 2002-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028513-A1 | METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | SMN1; SMN2, INA, NLN | TP53 3528/4885SMN1; SMN2 1/4885MAPK1 2537/4885 |
| US-20110178040-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | MMP1, MYLK, MMP8 | TP53 74/4885SMN1; SMN2 2014/4885MAPK1 1795/4885 |
| US-20160331727-A9 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | MMP1, MYLK, MMP8 | TP53 74/4885SMN1; SMN2 2014/4885MAPK1 1795/4885 |
| US-20160000757-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | MMP1, MYLK, MMP8 | TP53 74/4885SMN1; SMN2 2014/4885MAPK1 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.